Refractory anemia with excess of blasts
Refractory anemia with excess of blasts (RAEB) is a type of myelodysplastic syndrome (MDS), a group of diseases in which the bone marrow does not make enough healthy blood cells. RAEB is characterized by the presence of too many immature blood cells (blasts) in the bone marrow and blood, and too few healthy blood cells in the body.
Classification
RAEB is further classified into two subtypes: RAEB-1 and RAEB-2, based on the percentage of blasts in the bone marrow and blood. This classification is done according to the World Health Organization (WHO) criteria.
Symptoms
Patients with RAEB may experience symptoms such as fatigue, shortness of breath, easy bruising or bleeding, and increased risk of infections due to a decrease in healthy blood cells. Some patients may not have any symptoms at the time of diagnosis and the disease may be discovered during routine blood tests.
Diagnosis
Diagnosis of RAEB is based on blood tests, bone marrow examination, and cytogenetic analysis. The Complete blood count (CBC) may show low levels of red blood cells, white blood cells, and platelets. Bone marrow examination reveals an excess of blasts. Cytogenetic analysis can identify specific genetic changes that are associated with RAEB.
Treatment
Treatment for RAEB is aimed at reducing the symptoms, improving quality of life, and extending survival. Treatment options may include supportive care, drug therapy, and stem cell transplantation. The choice of treatment depends on various factors such as the patient's age, overall health, and the specific characteristics of the disease.
Prognosis
The prognosis for patients with RAEB varies widely and depends on several factors, including the subtype of RAEB, the patient's age and overall health, and the specific genetic changes present in the disease.
See also

This article is a hematology stub. You can help WikiMD by expanding it!
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
